September 22, 2023
TAG Response to TB Preventive Therapy Price Cut Announcement from USAID and PEPFAR
Statement / Press
TAG welcomes the joint announcement from USAID and PEPFAR at the CDC’s “Prevent TB to End TB” event on the sidelines of the United Nations High-Level Meeting on TB that they have secured a 30% price reduction on the tuberculosis preventive treatment (TPT) regimen called 3HP, taking the price from…
September 20, 2023
New TAG Analysis: Nearly All Countries “Far Off Track” of Meeting TB Research Targets Despite Publicly Reaffirming Commitments at UN
Statement / Press
As international dignitaries and political leaders gather in New York City this week for the United Nations High-Level Meeting (HLM) on TB, a sobering new analysis from Treatment Action Group (TAG) shows that governments failed to meet previous commitments to fund TB research.
September 19, 2023
At This Week’s UN General Assembly High-Level Meeting on Tuberculosis, the 1/4/6×24 Campaign Calls on Political Leaders to Take Urgent Action for Equitable Access to Shorter, Safer TB Regimens
Statement / Press
Ahead of the United Nations General Assembly High-Level Meeting on the Fight Against Tuberculosis, the 1/4/6×24 Campaign is sounding the alarm that the political declaration commits neither the funding nor the actions needed to expand access to the best-available TB regimens and diagnostics.
September 19, 2023
TAG Reaction to the Price of GeneXpert Tests
Statement / Press
Following intense pressure from TB-affected communities and civil society, Danaher’s price reduction of Xpert tests for TB and resistance to rifampicin (MTB/RIF Ultra) from $9.98 to $7.97 is a significant step forward that will help increase access to a lifesaving TB test and support countries to make progress toward closing…
September 19, 2023
Far Off Track: Funding for TB Research, 2018 – 2022
Publication
United Nations High-Level Meeting on TB Policy Note. At the first United Nations High-Level Meeting (HLM) on TB back in 2018, UN member states pledged “to mobilize sufficient and sustainable financing, with the aim of increasing overall global investments to 2 billion dollars […] in funding annually for tuberculosis research”…
September 12, 2023
TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023
Statement / Press
Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV,…
August 16, 2023
Information Note: New Fair Share Funding Targets for TB Research 0.1% -> 0.15%
Publication
In 2017 Treatment Action Group and partners introduced the “fair share” funding targets for TB research.
August 10, 2023
Letter to Dr. Jeanne Marazzo, New Director NIAID
Letter / Comment
We’re excited to welcome Dr. Jeanne Marazzo as the first woman and openly LGBTQ+ Director of the National Institute of Allergy and Infectious Diseases (NIAID).
August 1, 2023
Open letter: Requesting Clarification on the Recent Deal on Generic Bedaquiline Supply
Letter / Comment
TAG, Partners In Health, and MSF Access Campaign sent an open letter to Johnson & Johnson requesting detailed responses to questions and concerns regarding the deal with the Global Drug Facility to supply generic bedaquiline to low- and middle-income countries that excludes South Africa, 10 EECA countries, and China.
July 20, 2023
2023 Pipeline Report
Pipeline Report
Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).
July 13, 2023
TAG Encouraged by J&J Deal to Reduce Bedaquiline Prices, but Company’s Action Falls Short of Community Demands
Statement / Press
After over a year of sustained advocacy from the TB community demanding that Johnson & Johnson publicly commit to non-enforcement or withdrawal of secondary patents on bedaquiline filed in 66 low- and middle-income countries (LMICs)…
July 11, 2023
Open Letter: Urgent Action Necessary for Equitable Access to Bedaquiline in All Countries with High Burdens of TB, MDR-TB, and TB/HIV
Letter / Comment
TAG and 82 other organizations and 106 individuals representing TB-affected communities and civil society sent an open letter to Johnson & Johnson calling on the company…
July 11, 2023
An Activist’s Protocol Review Toolkit
Publication
An Activist’s Protocol Review Toolkit is designed to facilitate community participation in the development and review of clinical trials protocols.
June 20, 2023
2022 Annual Report
Publication
As we close another year of unprecedented challenges and achievements, I’m honored to share with you Treatment Action Group’s (TAG) 2022 Annual Report.
June 16, 2023
The ABC for a TB Activist: 1/4/6×24 Campaign and Supportive Diagnostics
Webinar / Presentation
On 15 June, 2023, TB Europe Coalition (TBEC) organized a webinar featuring a presentation by Treatment Action Group’s TB Project Officer, David Branigan, on the practical actions advocates can take to promote the adoption and scale up of shorter, safer 1/4/6 regimens for TB prevention and the treatment of drug-sensitive…